Biology and therapeutic targeting of molecular mechanisms in MPNs
J How, JS Garcia, A Mullally - Blood, 2023 - ashpublications.org
Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell disorders
characterized by activated Janus kinase (JAK)–signal transducer and activator of …
characterized by activated Janus kinase (JAK)–signal transducer and activator of …
[HTML][HTML] Recent advances in therapies for primary myelofibrosis
W Vainchenker, N Yahmi, V Havelange, C Marty… - Faculty …, 2023 - ncbi.nlm.nih.gov
Primary myelofibrosis (PMF), polycythemia vera (PV) and essential thrombocythemia (ET)
form the classical BCR-ABL1-negative myeloproliferative neoplasms (MPNs) that are driven …
form the classical BCR-ABL1-negative myeloproliferative neoplasms (MPNs) that are driven …
Development of resistance to type II JAK2 inhibitors in MPN depends on AXL kinase and is targetable
T Codilupi, J Szybinski, S Arunasalam, S Jungius… - Clinical cancer …, 2024 - AACR
Purpose: Myeloproliferative neoplasms (MPN) dysregulate JAK2 signaling. Because clinical
JAK2 inhibitors have limited disease-modifying effects, type II JAK2 inhibitors such as …
JAK2 inhibitors have limited disease-modifying effects, type II JAK2 inhibitors such as …
Advances in the design and discovery of next-generation janus kinase-2 (JAK2) inhibitors for the treatment of myeloproliferative neoplasms
ABSTRACT Introduction Myeloproliferative neoplasms (MPNs) are rare hematopoietic
disorders driven by mutations in the JAK-STAT signaling pathway genes. While JAK2 …
disorders driven by mutations in the JAK-STAT signaling pathway genes. While JAK2 …
[HTML][HTML] Exploring the Antiviral Potential of Artemisia annua Through JAK-STAT Pathway Targeting: A Network Pharmacology Approach
Background: Artemisia annua, a plant with antiviral potential, has shown promise against
various viral infections, yet its mechanisms of action are not fully understood. This study …
various viral infections, yet its mechanisms of action are not fully understood. This study …
Investigational drugs in early phase trials for myelofibrosis
S Arora, P Vachhani, P Bose - Expert Opinion on Investigational …, 2024 - Taylor & Francis
Introduction Myelofibrosis (MF) is a chronic myeloproliferative neoplasm characterized by
bone marrow fibrosis, cytopenias, and organomegaly. Four JAK inhibitors are US-FDA …
bone marrow fibrosis, cytopenias, and organomegaly. Four JAK inhibitors are US-FDA …
Recent advances in JAK2 inhibition for the treatment of myelofibrosis
N Rippel, M Kremyanskaya - Expert Opinion on Pharmacotherapy, 2024 - Taylor & Francis
Introduction Myelofibrosis (MF) is a BCR-ABL-negative myeloproliferative neoplasm
characterized by splenomegaly, constitutional symptoms, cytopenias, a potential for …
characterized by splenomegaly, constitutional symptoms, cytopenias, a potential for …
Janus kinase inhibitor monotherapy and combination therapies for myelofibrosis: what's the current standard of care?
Introduction JAK inhibitors (JAKi) have changed the treatment paradigm of myelofibrosis
(MF). Currently, 4 JAKis are approved in the US as monotherapy (mono) to treat patients …
(MF). Currently, 4 JAKis are approved in the US as monotherapy (mono) to treat patients …
Emerging drug profile: JAK inhibitors
A Coltoff, A Kuykendall - Leukemia & Lymphoma, 2024 - Taylor & Francis
Dysregulated JAK/STAT hyperactivity is essential to the pathogenesis of myelofibrosis, and
JAK inhibitors are the first-line treatment option for many patients. There are four FDA …
JAK inhibitors are the first-line treatment option for many patients. There are four FDA …
Exploring the interplay of kinases and transcription factors in immunometabolism
The complex interplay between kinases and transcription factors is fundamental to the
burgeoning field of immunometabolism, which investigates the intersection of cellular …
burgeoning field of immunometabolism, which investigates the intersection of cellular …